SURAKSHA NSE filing

Suraksha Diagnostics Q2 FY27 PAT Up 69%, EBITDA Up 45% YoY

The RealCase readHigh impact Positive

Suraksha Diagnostics reported strong Q2 FY27 results with PAT up 69% YoY to ₹14.95 crore and EBITDA up 45% YoY to ₹36.32 crore. H1 FY27 saw PAT grow 54% YoY to ₹27.80 crore. The company opened five new centers and plans to focus on sustainable growth and disciplined expansion.

Why it matters

The substantial percentage increase in Profit After Tax (PAT) and EBITDA, coupled with positive operational growth and strategic expansion, indicates a strong financial performance that is likely to have a significant positive impact on the company's valuation and investor confidence.

The market read

The company reported significant year-on-year growth in key financial metrics like Profit After Tax (PAT) and EBITDA for both the quarter and half-year ended September 30, 2026. Operational highlights include an increase in test volumes and patient numbers, along with strategic network expansion.

Suraksha Diagnostic Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. For H1 FY27, the company reported a Total Income of ₹189.31 crore (₹1893.09 million), an increase of 24% year-on-year. EBITDA grew by 37% to ₹67.85 crore (₹678.47 million), and Profit After Tax (PAT) rose by 54% to ₹27.80 crore (₹277.96 million).

In Q2 FY27, Suraksha Diagnostics saw its Total Income reach ₹100.58 crore (₹1005.75 million), a 26% year-on-year increase. EBITDA saw a significant jump of 45% to ₹36.32 crore (₹363.17 million), while PAT grew by an impressive 69% to ₹14.95 crore (₹149.50 million).

Operationally, total tests increased by 5% to 2.32 million in Q2 FY27, and total patients grew by 12% to 0.42 million. The company also expanded its network by opening five new centers, comprising two hub centers and three spoke centers, aligning with its strategy to build clusters and increase density. Ms. Ritu Mittal, Joint Managing Director & CEO, commented that the performance was supported by sustained growth in patient and test volumes, and the progressive maturing of recently commissioned centers. She also highlighted the potential of Suraksha Genomics and the company's focus on driving sustainable growth, improving contributions from maturing centers, and pursuing disciplined expansion into new markets.

Filing to action

What to do with a filing like this

Suraksha Diagnostic Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Suraksha Diagnostic Limited. Read the original for the full detail.

View original filing